Download Eliquis (Atrial Fibrillation) - Analysis and Forecasts to 2022 Brochure

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Transcript
Brochure
More information from http://www.researchandmarkets.com/reports/2152224/
Eliquis (Atrial Fibrillation) - Analysis and Forecasts to 2022
Description:
Eliquis (Atrial Fibrillation) – Analysis and Forecasts to 2022
Summary
GlobalData’s pharmaceuticals report, “Eliquis (Atrial Fibrillation) – Analysis and Forecasts to 2022” provides
Eliquis global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors
impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period
(2012-2022). The report also includes information on Atrial Fibrillation market. This report is built using data
and information sourced from GlobalData’s proprietary databases, primary and secondary research using
Company’s corporate website, SEC filings, investor presentations and featured press releases, both from
company and industry-specific third party sources, put together with in-house analysis, by GlobalData's
team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Eliquis including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Eliquis including efficacy, safety, pricing, competition and other details which influence
its sales potential
- Global sales forecast for 2012-2022 for Eliquis
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales
potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets
Keywords
Eliquis, apixaban, oral anticoagulant, stroke or systemic embolism, stroke prevention, Atrial Fibrillation,
prevention of venous thromboembolic events
Contents:
1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Atrial Fibrillation Market
2.2 Epidemiology
2.3 Etiology and Risk Factors
2.3.1 Symptoms associated with AF
2.4 GlobalData Analysis and Forecasts Report Guidance
3 Atrial Fibrillation: Market Characterization
3.1 Atrial Fibrillation Market
3.2 Atrial Fibrillation Market Forecasts and CAGR
3.3 Drivers of Atrial Fibrillation Market
3.3.1 High Unmet need
3.3.2 Strong Pipeline
3.3.3 Increase in prevalence and ageing populations
3.3.4 Organisation of Awareness Campaigns
3.4 Barriers in Atrial Fibrillation Market
3.4.1 Limitations in established therapies
3.4.2 High cost of emerging therapies
4 Classification in Atrial Fibrillation: Introduction
4.1 AF Classification
4.1.1 Pathophysiology of AF
4.1.2 Diagnosis in Atrial Fibrillation
4.1.3 Impact of Atrial Fibrillation
5 Treatment Options and Management in Atrial Fibrillation
5.1 Rate control and Rhythm control
5.2 Rate Control Versus Rhythm Control
6 Eliquis
6.1 Introduction
6.2 Mechanism of Action
6.3 Clinical Studies
6.4 Approval History
6.5 Factors Affecting Sales of Eliquis
6.5.1 Superior Efficacy and Safety Profile
6.5.2 Speedy action to Warfarin
6.5.3 Early entry into the market
6.5.4 Superior bleeding profile among competitors
6.6 Drug Evaluation
6.6.1 Drug Risk Benefit Score
6.6.2 Intensity of Competition
6.7 Sales Forecast
6.7.1 Target Patient Pool of Eliquis
6.7.2 Dosing
6.7.3 Market Penetration
6.7.4 Annual Cost of Therapy
6.7.5 Global Sales Projections of Eliquis
7 Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Number of Patients Approved to Take the Drug
7.3.5 Net Penetration of Drug
7.3.6 Net Annual Dosing
7.3.7 Annual Cost of Therapy
7.4 Drug Sales Estimates Model
7.5 Contact Us
7.6 Disclaimer
7.7 Sources
1.1 List of Tables
Table 1: Epidemiology of Atrial Fibrillation (2011)
Table 2: Increase in the Risk of AF in The Presence of Risk Factors
Table 3: Stratification of All Risk Factors For Atrial Fibrillation
Table 4: Atrial Fibrillation Classification
Table 5: Treatment Guidelines For the Management of Atrial Fibrillation
Table 6: Drug Risk Benefit Score of Eliquis
Table 7: Eliquis, Atrial Fibrillation, Global, Annual Cost of Therapy ($), 2011
Table 8: Eliquis, Atrial Fibrillation, Global, Sales Forecasts ($m), 2012–2022
Table 9: Eliquis, Atrial Fibrillation, The US, Sales Forecasts ($m), 2012–2022
Table 10: Eliquis, Atrial Fibrillation, The UK, Sales Forecasts ($m), 2012–2022
Table 11: Eliquis, Atrial Fibrillation, France, Sales Forecasts ($m), 2012–2022
Table 12: Eliquis, Atrial Fibrillation, Germany, Sales Forecasts ($m), 2012–2022
Table 13: Eliquis, Atrial Fibrillation, Italy, Sales Forecasts ($m), 2012–2022
Table 14: Eliquis, Atrial Fibrillation, Spain, Sales Forecasts ($m), 2012–2022
Table 15: Eliquis, Atrial Fibrillation, Japan, Sales Forecasts ($m), 2012–2022
1.2 List of Figures
Figure 1: Atrial Fibrillation, Global, Market Size Forecasts ($bn), 2011–2022
Figure 2: Percentage Of Molecules (in Different Phases of Development) For Atrial Fibrillation
Figure 3: Increase of Prevalance Population in Atrial Fibrillation
Figure 4: Normal Heart Rhythm Vs Atrial Fibrillation
Figure 5: Broad classification of Patterns in Atrial Fibrillation
Figure 6: Disease States Associated with Atrial Fibrillation, By (%)
Figure 7: Therapeutic Goals in Patients with Atrial Fibrillation (AF)
Figure 8: Management of Newly Discovered Atrial Fibrillation (AF)
Figure 9: Drug Model Diagram of Eliquis
Figure 10: Eliquis, Atrial Fibrillation, Global, Sales Forecasts ($m), 2012–2022
Figure 11: Eliquis, Atrial Fibrillation, The US, Sales Forecasts ($m), 2012–2022
Figure 12: Eliquis, Atrial Fibrillation, The UK, Sales Forecasts ($m), 2012–2022
Figure 13: Eliquis, Atrial Fibrillation, France, Sales Forecasts ($m), 2012–2022
Figure 14: Eliquis, Atrial Fibrillation, Germany, Sales Forecasts ($m), 2012–2022
Figure 15: Eliquis, Atrial Fibrillation, Italy, Sales Forecasts ($m), 2012–2022
Figure 16: Eliquis, Atrial Fibrillation, Spain, Sales Forecasts ($m), 2012–2022
Figure 17: Eliquis, Atrial Fibrillation, Japan, Sales Forecasts ($m), 2012–2022
Figure 18: Eliquis, Atrial Fibrillation, Global, Sales Distribution, By Country (%), 2022
Figure 19: Patients Approved for the Drug
Ordering:
Order Online - http://www.researchandmarkets.com/reports/2152224/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Eliquis (Atrial Fibrillation) - Analysis and Forecasts to 2022
Web Address:
http://www.researchandmarkets.com/reports/2152224/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Site License:
USD 4000
Electronic (PDF) Single User:
USD 2000
Electronic (PDF) Enterprisewide:
USD 6000
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World